Search Results - "Guerini-Rocco E"

1223P Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study.

Authors: Ranghiero, A. Guerini Rocco, E. Rappa, A. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS717-S717. 1p.

1725P Claudin 18.2 determination in high-grade neuroendocrine neoplasms.

Authors: Gervaso, L. Lobrano, R. Pisa, E. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1016-S1016. 1p.

752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Le Saux, O. Borel, C. Ghiringhelli, F. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS515-S516. 2p.

High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role.

Authors: Ravenda, P. S. Zampino, M. G. Guerini-Rocco, E. et al.

Source: Annals of Oncology. May2017, Vol. 28 Issue 5, p1160-1160. 3/4p.

923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial.

Authors: Le Tourneau, C. Ghiringhelli, F. Saada, E.B. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS583-S583. 1p.

758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Saint-Ghislain, M. Abdeddaim, C. Chaltiel, R. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS518-S518. 1p.

557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Coutzac, C. Bigot, F. Vansteene, D. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS415-S415. 1p.

10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers.

Authors: Fusco, N. Sajjadi, E. Venetis, K. et al.

Source: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS25-S25. 1p.

18P Inter-tumour heterogeneity in breast cancers: The dynamic evolution of cancer genome during the metastatic process.

Authors: Fumagalli, C. Ranghiero, A. Gandini, S. et al.

Source: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS23-S23. 1p.

28P Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer.

Authors: Erber, R. Hartmann, A. Fasching, P. et al.

Source: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS25-S25. 1p.

152P Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC.

Authors: Gianoncelli, L Spitaleri, G Passaro, A et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

144P Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs.

Authors: Passaro, A Prelaj, A Spitaleri, G et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models.

Authors: Frascarelli C Venetis K Marra A et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Dec 16; Vol. 11 (1), pp. 141. Date of Electronic Publication: 2025 Dec 16.

Publication Type: Journal Article; Review

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Concordance of Actionable Driver Alterations Between Primary Lung Adenocarcinoma and Paired Thoracic Metastases: A Prospective Next-Generation Sequencing Study.

Authors: Bertolaccini L Lombardi M Chiari M et al.

Source: Cancers [Cancers (Basel)] 2026 May 28; Vol. 18 (11). Date of Electronic Publication: 2026 May 28.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Implementing digital pathology: qualitative and financial insights from eight leading European laboratories.

Authors: Matias-Guiu X Temprana-Salvador J Garcia Lopez P et al.

Source: Virchows Archiv : an international journal of pathology [Virchows Arch] 2025 Oct; Vol. 487 (4), pp. 815-826. Date of Electronic Publication: 2025 Mar 08.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE

Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.

Authors: Ranghiero A Rinaldi L Netti S et al.

Source: The journal of liquid biopsy [J Liq Biopsy] 2026 Apr 26; Vol. 12, pp. 100470. Date of Electronic Publication: 2026 Apr 26 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier B.V Country of Publication: United States NLM ID: 9918957761506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-1954 (Electronic) Linking ISSN: 29501954 NLM ISO Abbreviation: J Liq Biopsy Subsets: PubMed not MEDLINE

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.

Authors: Attili I Pellizzari G Bertolaccini L et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2026 Mar; Vol. 27 (2), pp. 259-268.e8. Date of Electronic Publication: 2025 Oct 03.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer.

Authors: Boehm KM El Nahhas OSM Marra A et al.

Source: Nature communications [Nat Commun] 2025 Mar 02; Vol. 16 (1), pp. 2106. Date of Electronic Publication: 2025 Mar 02.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis.

Authors: Valenza C Trapani D Porta FM et al.

Source: The oncologist [Oncologist] 2025 Feb 06; Vol. 30 (2).

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Molecular tumor board in patients with metastatic breast cancer.

Authors: Boscolo Bielo L Guerini Rocco E Crimini E et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Feb; Vol. 210 (1), pp. 45-55. Date of Electronic Publication: 2024 Oct 30.

Publication Type: Evaluation Study; Journal Article

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE